Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond

The introduction of collagenase Clostridium histolyticum (CCH) as the first and only FDA-approved non-surgical treatment for Peyronie’s disease (PD) has been an important step in its management. Our aim is to provide an overview of the historical origins of CCH and its development through FDA approval and beyond for the treatment of PD. A PubMed search using the terms Peyronie OR Peyronie’s AND collagenase and limited to clinical research...